Kenneth Hughes
Ludwig Institute for Cancer Research
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kenneth Hughes.
Neuroscience Letters | 1992
Diane P. Hanger; Kenneth Hughes; James R. Woodgett; Jean Pierre Brion; Brian H. Anderton
Glycogen synthase kinase-3 (GSK-3) reduced the mobility of human tau on SDS-PAGE, prevented binding of the monoclonal antibody (mAb), Tau.1, and induced binding of the mAb 8D8. Recombinant tau phosphorylated by GSK-3 aligned on SDS-PAGE with the abnormally phosphorylated tau (PHF-tau) associated with the paired helical filaments in Alzheimers disease brain. Phosphorylated serine396 (numbering of the largest human brain tau isoform) was identified as a binding site on tau for mAb 8D8. The localisation of GSK-3 within granular structures in pyramidal cells indicates that GSK-3 alpha and GSK-3 beta may have a role in the production of PHF-tau in Alzheimers disease.
The EMBO Journal | 1993
Kenneth Hughes; Eleni Nikolakaki; Simon E. Plyte; N F Totty; James R. Woodgett
Glycogen synthase kinase‐3 (GSK‐3) is a protein serine kinase implicated in the cellular response to insulin. The enzyme is the mammalian homologue of the zeste‐white3 (shaggy) homeotic gene of Drosophila melanogaster and has been implicated in the regulation of the c‐Jun/AP‐1 transcription factor. In mammals this protein serine kinase is encoded by two related genes termed GSK‐3 alpha and beta. Here, we demonstrate that these two proteins and the fruit fly protein are phosphorylated on tyrosine in vivo. Moreover, GSK‐3 beta activity and function are shown to be dependent on tyrosine phosphorylation. The modified tyrosine residue is conserved in all members of the GSK‐3 family and is equivalent to that required for activity by mitogen‐activated protein (MAP) kinases. However, unlike MAP kinases, GSK‐3 is highly phosphorylated on tyrosine and thus active in resting cells.
FEBS Letters | 1994
S.F.C. Mulot; Kenneth Hughes; James R. Woodgett; Brian H. Anderton; Diane P. Hanger
Extensive in vitro phosphorylation of a purified preparation of control human brain tau consistently produces four rather than, as previously believed, three tau species on SDS‐PAGE. The species thus generated are shifted on SDS‐PAGE to positions that match those of PHF‐tau isolated from Alzheimers disease brain. A mixture of recombinant human tau isoforms phosphorylated by GSK‐3β gave similar results to those obtained with control human brain tau. In vitro phosphorylation of the individual recombinant isoforms by GSK‐3β showed that the four bands of PHF‐tau are likely to consist of isoforms 3R,0 alone; 4R,0 with 3R,29; 4R,29 with 3R,58 and 4R,58 alone.
Journal of General Virology | 2001
Ad Vos; Andreas Neubert; Elke Pommerening; Thomas Müller; Leopold Döhner; L. Neubert; Kenneth Hughes
The immunogenic properties of an E1-deleted, human adenovirus type 5 (Ad5) vaccine virus with activity against rabies were examined in mice, foxes and dogs using different routes of administration. NMRI mice received 10(5.8), 10(5.3), 10(4.3), 10(3.3) and 10(2.3) TCID(50) by peroral or intramuscular (i.m.) administration. Furthermore, six mice received 10(5.8) TCID(50) intracerebrally (i.c.). The construct elicited marked seroconversion in mice after oral administration. Immunoreactivity in mice was even more pronounced i.m. and i.c. After direct oral administration (10(8.0) TCID(50)) in foxes, six of eight animals developed rabies virus-neutralizing antibodies (VNA). All foxes immunized by direct injection (10(7.7) TCID(50)) in the membrane of the jejunum were shown to seroconvert. Pre-existing immunity against canine adenovirus did not hinder the development of rabies VNA after oral application of the construct (10(8.0) TCID(50)). Fox cubs (24-29 days old) born from rabies-immune vixens were shown to develop very high levels of rabies VNA after i.m. administration (10(8.0) TCID(50)), indicating that the immunogenicity of the construct could surpass maternally transferred immunity. In dogs, the construct (10(8.0) TCID(50)) induced a very strong immune response after i.m. administration. However, no immune response was detectable in dogs after direct oral administration (10(8.3) TCID(50)) or after endoscopic deposition in the smaller intestine (10(8.0) TCID(50)). Hence, it must be concluded that the construct is not suitable for oral vaccination of dogs against rabies.
Biochimica et Biophysica Acta | 1995
Trevor Martin; Stephen H. Hughes; Kenneth Hughes; Michael Dawson
The protein coding regions of the PrP genes of six pigs were sequenced directly from PCR-amplified genomic DNA. All six sequences were identical. The gene encodes a protein of 257 amino acids and shows an overall similarity of 77 to 88% with the PrP sequences from other mammalian species. The significance of amino acids unique to the pig PrP are discussed.
Journal of General Virology | 1999
Linda Scobie; Chris Venables; Kenneth Hughes; Michael Dawson; Oswald Jarrett
The development of the antibody response to peptides of the transmembrane glycoprotein of bovine immunodeficiency virus (BIV) was followed over a period of 50 weeks in six cattle experimentally infected with the BIV(FL112) isolate. Antibody was detected by an enzyme immunoassay using either a linear or a cyclized peptide with structural features common to an immunodominant region of other lentiviruses. The assay was specific for BIV, detecting antibody in bovine sera to BIV(FL112) or BIV(R29) but not to six other common viruses of cattle. Antibody was present in the sera of all cattle inoculated with BIV(FL112) within 4 weeks of infection, peaked between 10 and 30 weeks and persisted in most cattle during the 50 weeks of observation. These features indicate that this assay may be useful in identifying cattle infected with other strains of BIV in the field.
Biochimica et Biophysica Acta | 1992
Simon E. Plyte; Kenneth Hughes; Eleni Nikolakaki; Bernd J. Pulverer; James R. Woodgett
Oncogene | 1993
Bernd J. Pulverer; Kenneth Hughes; Christopher C. Franklin; Andrew S. Kraft; Sally J. Leevers; James R. Woodgett
FEBS Journal | 1992
Kenneth Hughes; Bernd J. Pulverer; Panteli Theocharous; James R. Woodgett
Pigment Cell Research | 1994
James R. Woodgett; Bernd J. Pulverer; Simon E. Plyte; Kenneth Hughes; Eleni Nikolakaki